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Supplementary methods 
 
Genetic studies - datasets contributing to analysis 
Supplementary Table 3 describes the details of studies contributing individual participant-level data 
(IPD) to the genetic analysis. The participating studies are detailed below. 
 - Prospective cohort studies 
Twenty-five prospective cohort studies (including birth cohorts) contributed genotype and 
phenotype (either biomarkers, clinical events, or both) data to the genetic analysis. The designs of 
these studies have been described previously. 
 
From the UCL-LSHTM-Edinburgh-Bristol (UCLEB) Consortium: British Regional Heart Study (BRHS)1, 
the British Women's Heart and Health Study (BWHHS)2, the Caerphilly Prospective Study (CaPS)3, the 
Edinburgh Artery Study (EAS)4, the English Longitudinal Study of Aging (ELSA)5, the Edinburgh Type 2 
Diabetes Study (ET2DS)6, the Northwick Park Heart Study II (NPHS-II)7, the Whitehall-II (WHII) study8, 
and the MRC National Survey of Health and Development (MRC NSHD, 1946 British Birth Cohort)9. 
 
From the National Heart, Lung and Blood Institute (NHLBI) Candidate Gene Association Resource 
(CARe) Consortium: the Atherosclerosis Risk in Communities Study (ARIC)10, the Coronary Artery Risk 
Development in Young Adults (CARDIA) Study11, the Cleveland Family Study (CFS)12,13, the 
Cardiovascular Health Study (CHS)14, the Framingham Heart Study (FHS)15, and the Multi-Ethnic Study 
of Atherosclerosis (MESA)16. 
 
From the Health, Alcohol and Psychosocial factors In Eastern Europe (HAPIEE) study17: the Czech 
Republic (HAPIEE-CZ), Lithuania (HAPIEE-LT), Poland (HAPIEE-PL) and Russia (HAPIEE-RU) arms of the 
study. 
 
Also, the Copenhagen City Heart Study (CCHS)18, the MRC Ely Cohort19, the MRC Fenland Cohort20, 
the IMPROVE study21, the Prevention of Renal and Vascular Endstage Disease Study (PREVEND)22, 
and the Second Manifestations of Arterial Disease (SMART) Study23. 
 - Case-control and case-cohort studies 
Three nested case-control studies were included - the InterAct consortium of studies24, the Utrecht 
Cardiovascular Pharmacogenetics study (UCP)25 and the Women's Health Initiative (WHI)26. 
 - Intervention trials 
 3 
Five RCT studies were included - the Aspirin in Asymptomatic Atherosclerosis (AAA) trial27, the 
Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin 
(JUPITER) trial28, the PROSPER trial follow-up study29, the Thrombosis Prevention Trial follow-up 
study (TPT)30, and the Women's Genome Health Study (WHGS)31. These trials were treated as 
prospective cohorts for the purposes of these analyses.  
 - GWA studies 
Two GWA study consortia contributed data.  
Data from the Meta-Analysis of Glucose and Insulin-related traits Consortium (MAGIC) were included 
in the form of single-SNP lookups1. Estimates of the association between the lead HMGCR SNPs and 
fasting insulin were extracted from analysis using the Illumina Metabochip SNP genotyping platform. 
 
An estimate of the association of the lead HMGCR SNPs with body weight were accessed from 
publicly available data from the Genetic Investigation of Anthropometric Traits (GIANT) Consortium32 
at http://csg.sph.umich.edu/locuszoom/ (Accessed 11 August 2011). 
 
From the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium33, we included the 
following studies: deCODE34,35, the Diabetes Gene Discovery Group (DGDG)36, the Diabetes Genetics 
Initiative (DGI)36,37, the European Special Population Network (EUROSPAN)37–40, the Cooperative 
Health Research in the Region of Augsburg, Southern Germany Study (KORAgen)41–43, the Rotterdam 
Study44, and the Wellcome Trust Case-Control Consortium (WTCCC)45. 
 
 
Genetic studies - Biomarker measurement and definitions 
Availability of biomarker data in genetic studies is detailed in Supplementary Table 4. 
All biomarkers were measured using validated protocols and assays reported previously. Biomarker 
data used in the present analyses were taken from either the baseline phase of data collection in each 
study, or the next phase soonest after baseline at which data on the greatest number of biomarkers 
were available. Where certain biomarker variables were unavailable at the principal survey phase, 
they were included from closest subsequent phase with data available. 
 
In some studies (BRHS, HAPIEE-Russia, HAPIEE-Lithuania, HAPIEE-Poland, HAPIEE-Czech Republic, 
CaPS and Whitehall II), LDL-cholesterol (LDL-C) concentration was not measured directly but was 
derived using the Friedewald formula46. In studies where data on total, LDL- and non-HDL-cholesterol 
were available in units of mg/L, these variables were converted to mmol/L using a multiplication 
factor of 0.02586. 
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 Genetic studies - T2DM clinical outcome 
Definitions of T2D cases differed between studies. Common definitions were therefore set in order to 
accommodate data from as many studies as possible whilst avoiding reporting or measurement bias. 
Studies used validated biochemical criteria or physician diagnosis, and others self-report to identify 
T2D cases (details are given in Supplementary Table 5). We included all T2D cases, although, where 
possible, unvalidated self-reported cases were excluded. 
 
In the majority of studies, the type of diabetes mellitus (DM) - i.e. type 1, type 2 or others - was not 
recorded. However, given the relative preponderance of type 2 DM in the general population and the 
mean age of study participants, we assumed that the overwhelming majority of cases were T2D. In 
ET2DS, where all participants were diabetic, individuals free from T2D from EAS were used as controls. 
EAS was selected as the most appropriate source of controls since its participants were recruited from 
the same area of Scotland as those in ET2DS. 
 
 
Genetic studies - SNP selection 
The aim of the SNP selection process was to identify a minimal set of variants with associations with 
LDL-C concentration that were both statistically strong and of greatest possible magnitude.  Moreover, 
the highest possible minor allele frequency (MAF) was sought to increase the power of the analysis. 
To identify suitable SNPs for use as instruments in this analysis, 4,678 individuals in the Whitehall II 
study (an observational longitudinal study of UK civil servants) were genotyped using the IBC 
HumanCVD BeadChip (Cardiochip), a gene-centric platform including c. 48,000 SNPs in around 2,100 
genes implicated in CVD47.  
 
Associations of the 38 SNPs included on the array at the HMGCR locus with LDL-C concentration were 
estimated using univariate linear regression models in PLINK 48. We evaluated suitability of SNPs at 
the HMGCR locus for inclusion based on these parameters: i) p-value <1x10-5 for association with LDL-
C; ii) linkage disequilibrium (LD) between SNPs assessed using data from the 1000 Genomes Project 
Pilot 1 (using SNAP pairwise LD tool - www.broadinstitute.org/mpg/snap/); and, iii) a minor allele 
frequency (MAF) ≥20%. Within the 38 SNPs at the HMGCR locus included on the Cardiochip, we 
retained only one SNP from groups in strong LD (r2>0.85) (Supplementary Table 1). Two SNPs, 
rs17238484 and rs12916 (between-SNP LD R2=0.37) were selected for analysis in the collaborating 
studies, with the rs17238484 SNP designated the lead variant. Both rs1723848449 and rs1291650 have 
previously been associated with plasma LDL-C at a genome-wide level of statistical significance. 
Genotype data in collaborating studies were excluded if the allele call rate was <90% or the Hardy-
Weinberg equilibrium (HWE) p-value was <1x10-5 (Supplementary Table 2). 
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To confirm the influence of HMGCR mRNA transcript levels on LDL, we carried out imputation and 
eQTL analysis of a liver gene expression dataset and genotypes for 966 human liver samples of 
unrelated European-Americans51. Colocalisation analysis was run using the liver eQTL data together 
with LDL summary data from a publicly available meta-analysis of LDL in more than 100,000 
individuals of European ancestry 50, as previously described (http://arxiv.org/abs/1305.4022). 
 
In studies where the lead HMGCR SNPs were not directly genotyped, proxy SNPs were used in the 
analysis. Proxies were defined on the basis of their LD with each lead SNP, with a threshold of r2>0.85. 
 
 
Genetic studies - genotyping and genotype data quality control 
Genotypes were coded as 0 (GG), 1 (GT), and 2 (TT) and included in regression models as the 
predictor (independent) variable. Since this coding assumes the T allele to be the effect allele, the 
sign of regression model beta-coefficients was inverted in order to present the effect of G allele 
carriage. Existing genotype data were used where available, and new genotyping commissioned 
where necessary. Details of genotyping platforms and data quality control are shown in 
Supplementary Table 2. 
 
 
Genetic studies - statistical analysis - Participant inclusion and relatedness 
Only individuals with data available on the lead HMGCR SNPs (or their proxies) and at least one 
phenotype (biomarker or clinical endpoint) were included in the analysis. To avoid bias caused by 
relatedness, in studies where data on family structure were available, only the eldest member of a 
group of related individuals was included. 
 - Associations of HMGCR genotype with biomarkers 
Mean differences in biomarkers between genotype classes were estimated using the 'metan' 
command in Stata v11.2 (Stata Corp., College Station, Texas), using an inverse-variance fixed effects 
meta-analysis model. For loge biomarker variables, the summary meta-analysis estimate was 
exponentiated and subtracted from 1 to yield a proportional difference in geometric means between 
genotype classes. The Stata 'regress' command (or equivalent in other computer packages) was used 
to estimate the mean difference in biomarker level associated with carriage of each additional copy 
of the lead SNP effect allele. Here too, the proportional difference in geometric mean was estimated 
for loge-transformed variables the same technique. Within-study estimates of the per-allele SNP 
association with each biomarker were combined using inverse-variance fixed-effects meta-analysis. 
 - Subgroup analysis of SNP-biomarker associations 
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In order to assess potential effect modification or confounding in our estimates of genetic 
associations with biomarkers, we stratified the analysis according to a number of pre-specified 
subgroups. These were: 
i. Within-study tertiles of non-HDL-C (as a surrogate for LDL-C for data were available in a 
greater number of studies);  
ii. Users and non-users of lipid-lowering drugs; 
iii. Normal weight (BMI <25), overweight (BMI ≥25-<30) and obese (BMI ≥30) individuals; 
iv. Males and females; and, 
v. Individuals with and without prevalent or incident T2D 
Biomarker associations were estimated as described above, and heterogeneity between subgroup 
strata assessed with meta-regression modelling of combined meta-analysis effect estimates (using 
the 'metareg' command in Stata). These models sought differences between binary subgroup strata, 
and evidence of linear association in subgroups with ≥3 strata. 
 - Associations of HMGCR genotype with T2D outcome 
Where data were available, the association of the lead HMGCR SNPs with risk of prevalent and 
incident T2D was estimated under genotypic and additive models, similarly to the associations with 
biomarkers. Odds ratios (ORs) for rs17238484 GT vs TT and for GG vs TT genotype, and for rs12916 
AA vs AG and AA vs GG were estimated using fixed effects Mantel-Haenszel meta-analysis (Stata 
'metan' command). The OR per LDL-lowering allele for each SNP was estimated using logistic 
regression models within each study (Stata 'logit' command), and within-study estimates were 
combined using inverse-variance fixed effects meta-analysis in Stata, as above. Meta-analyses were 
repeated using a random effects model. 
 
 
Statin treatment trials included 
Trials of participants with organ transplants or on dialysis were excluded, as were those with 
differences in participant follow-up between treatment arms, or which investigated dual lipid-
lowering therapy. These meta-analyses included data from 13 intervention trials comparing statin 
treatment with placebo (ten trials) or standard care (three trials)52, and from five trials comparing 
high- to moderate-dose statin treatment53, respectively. At the time of their publication, data were 
unavailable from three eligible trials (CARE54, SPARCL55 and LIPS56). Data on new-onset T2D have 
subsequently been published for SPARCL57, and data for LIPS were made available by its industrial 
sponsor for the present analysis, which now includes 20 trials. 
 
Below are the randomised statin trials included in the present analysis, with references to their 
respective published reports. The trials are listed in chronological order of publication: 
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Scandinavian Simvastatin Survival Study (4S)58 
West of Scotland Coronary Protection Study (WOSCOPS)59 
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS TexCAPS)60 
Long-Term Intervention with Pravastatin in Ischaemic Disease Study (LIPID)61 
GISSI-Prevenzione 62 
Lescol® Intervention Prevention Study (LIPS)63 
Heart Protection Study (HPS)64 
Pravastatin in elderly individuals at risk of vascular disease (PROSPER)65 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial - Lipid-lowering 
Treatment arm (ALLHAT-LLT)66 
Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA)67  
Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 
22 (PROVE-IT TIMI 22)68 
A to Z Trial69 
Treating to New Targets Trial (TNT)70 
Incremental Decrease in End Points Throught Aggressive Lipid Lowering Study (IDEAL)71  
Stroke Prevention by Aggresive Reduction in Cholesterol Levels Trial (SPARCL)55 
MEGA Trial72 
Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)73 
GISSI-Heart Failure Trial (GISSI-HF)74 
Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin 
(JUPITER)75 
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine  (SEARCH)76 
 
Statin treatment trials - T2D outcome definition 
Diagnostic criteria for T2D varied among the 20 contributing trials, but included one or more of, (i) 
physician-reported diagnosis of T2D; (ii) commencement of glucose-lowering medication; or, (iii) 
fasting glucose >7.0mmol/L (on at least one occasion; see Table 1); and (iv) T2D defined according to 
World Health Organisation 1999 criteria.  In a subset of trials, T2D was diagnosed by the presence of 
elevated fasting glucose. In trials where plasma glucose was measured frequently, T2D was diagnosed 
after two elevated glucose readings, and after one in trials with less frequent testing. 
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Supplementary results 
 
HMGCR SNP expression and co-localisation analysis 
Co-localisation analysis yields a high probability of a shared signal for the eQTL in HMGCR and LDL-C 
lipid biomarkers, suggesting that HMGCR gene expression mediates the LDL signal (Supplementary 
Figure 2). Extensive linkage disequilibrium at the eQTL signal, however, limits the power of co-
localisation analysis at this locus. The fact that other genes 1Mb around the HMGCR gene have a 
probability of co-localisation less than 3% increases the probability that HMGCR is the gene 
responsible for the LDL signal.  
 
The T allele of rs12916 is associated with lower expression of HMGCR in the liver (effect = 0.054, 
standard error=0.012; p=1.30x10-5; MAF = 0.39, imputation R2= 0.99). Out of all the SNPs used in the 
co-localisation analysis, rs12916 was the SNP with the highest probability of driving the shared 
association between eQTL and LDL-C (54%, see Supplementary Figure 1). Data were unavailable in 
the dataset for the HMGCR rs17238484 SNP or its proxies. 
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Supplementary Table 1 - SNPs within 55kb of HMGCR on the Cardiochip platform and their associations with LDL-C in the Whitehall II study  
 
 
   
Association with LDL-C  
Selected 
for analysis SNP Chr. 
Base pair 
position 
No. of 
participants 
LDL-C β-
coefficient 
95% Confidence 
interval 
Regression model 
p-value LDL-C R2 F-statistic MAF 
 rs12916 5 74692295 4,666 0.12 0.08 to 0.17 6.0e-09 7.2e-03 33.96 0.40 
 rs10038095 5 74673467 4,667 0.12 0.07 to 0.16 5.8e-08 6.3e-03 29.51 0.38 
 rs12654264 5 74684359 4,665 0.12 0.07 to 0.16 8.3e-08 6.1e-03 28.83 0.38 
 rs3846662 5 74686840 4,661 0.11 0.07 to 0.15 9.8e-08 6.1e-03 28.51 0.43 
 rs17238484 5 74684252 4,658 0.12 0.07 to 0.17 1.0e-06 5.1e-03 23.96 0.23 
 rs10474434 5 74680437 4,671 0.12 0.07 to 0.17 1.5e-06 4.9e-03 23.17 0.23 
 rs3804231 5 74732535 4,672 0.14 0.07 to 0.20 1.5e-05 4.0e-03 18.75 0.13 
 rs2303152 5 74677463 4,677 0.07 0.00 to 0.14 .038 9.2e-04 4.31 0.10 
 rs17238540 5 74691254 4,673 -0.12 -0.25 to 0.02 .098 5.9e-04 2.74 0.02 
 rs3761739 5 74667257 4,672 0.04 -0.02 to 0.10 .152 4.4e-04 2.05 0.15 
 rs3761740 5 74667889 4,676 0.04 -0.03 to 0.11 .229 3.1e-04 1.45 0.09 
 rs17238372 5 74672629 4,677 0.13 -0.08 to 0.34 .231 3.1e-04 1.44 0.01 
 rs17648288 5 74732394 4,674 0.04 -0.03 to 0.11 .258 2.7e-04 1.28 0.09 
 rs16872536 5 74714241 4,673 0.04 -0.03 to 0.11 .274 2.6e-04 1.20 0.08 
 rs10474435 5 74693036 4,674 0.10 -0.09 to 0.29 .285 2.5e-04 1.15 0.01 
 rs16872526 5 74711473 4,664 0.04 -0.03 to 0.11 .29 2.4e-04 1.12 0.08 
 rs10038689 5 74718367 4,677 0.10 -0.09 to 0.29 .302 2.3e-04 1.07 0.01 
 rs17244848 5 74679426 4,632 0.03 -0.04 to 0.11 .336 2.0e-04 0.92 0.09 
 rs17244939 5 74666852 4,671 -0.07 -0.22 to 0.08 .369 1.7e-04 0.81 0.02 
 rs4704209 5 74670229 4,670 0.04 -0.05 to 0.13 .42 1.4e-04 0.65 0.06 
 rs3889900 5 74741803 4,678 - - - - - <0.01 
 rs17238477 5 74680879 4,678 - - - - - <0.01 
 rs17244715 5 74667984 4,678 - - - - - <0.01 
 rs17238519 5 74689134 4,671 - - - - - <0.01 
 rs17244946 5 74667566 4,676 - - - - - <0.01 
 rs17238435 5 74677582 4,678 - - - - - <0.01 
 rs17244708 5 74667603 4,675 - - - - - <0.01 
 rs17244890 5 74688485 4,671 - - - - - <0.01 
 rs17238337 5 74667055 4,675 - - - - - <0.01 
 rs16872532 5 74713739 4,678 - - - - - <0.01 
 rs17244722 5 74668837 4,676 - - - - - <0.01 
 rs17244960 5 74680009 4,676 - - - - - <0.01 
 rs17244883 5 74688082 4,676 - - - - - <0.01 
 rs17238449 5 74678164 4,678 - - - - - <0.01 
 rs17244757 5 74672460 4,676 - - - - - <0.01 
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Association with LDL-C  
Selected 
for analysis SNP Chr. 
Base pair 
position 
No. of 
participants 
LDL-C β-
coefficient 
95% Confidence 
interval 
Regression model 
p-value LDL-C R2 F-statistic MAF 
 rs17244729 5 74669229 4,676 - - - - - <0.01 
 rs17238554 5 74693408 4,674 - - - - - <0.01 
 rs17238575 5 74680466 4,671 - - - - - <0.01 
SNPs are ranked on p-value and β-coefficient; β-coefficients are reported on the log scale. For SNPs where β-coefficient is absent, no variation in genotype was observed in 
the Whitehall II study sample owing to very low minor allele frequency and consequently a regression model could not be fitted. 
Abbreviations: Chr – chromosome; R2 – proportion of variance explained; MAF – minor allele frequency 
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Supplementary Table 2 – Genotype information for studies contributing individual participant-level data 
  
rs17238484 rs12916 
Study Genotyping platform 
SNP 
call 
rate 
(%) 
Proxy SNP used  
 (LD, r2)* GG  GT TT 
MAF 
(%) 
HWE 
SNP 
call 
rate 
(%) 
Proxy SNP used  
 (LD, r2)* TT TC CC MAF (%) 
HWE 
χ2 p χ2 p 
AAA KASPAR  - 1,358 792 100 22.0 1.31 0.25 
95.9 - 999 943 321 35.0 16.12 6.0x10-5 
ARIC IBC Cardiochip  - 5,635 3,386 565 23.6 3.53 0.06 
100.0 - 3,432 4,528 1,628 40.6 4.16 0.04 
BRHS KASPar 98.3 - 2,328 1,325 223 27.4 3.56 0.06 97.3 - 1,620 1,562 657 37.5 66.5 3.5x10-16 
BWHHS IBC Cardiochip  - 2,010 1,245 185 23.5 0.19 0.67 
99.9 - 1,218 1,668 557 40.4 0.12 0.72 
CaPS KASPar  - 837 498 70 22.7 0.14 0.71 
98.5 - 563 627 216 37.7 3.55 0.06 
CARDIA IBC Cardiochip  - 836 527 80 23.8 0.07 0.80 
100.0 - 472 736 235 41.8 3.38 0.07 
CCHS ABI TaqMan 90.5 - 5,532 3,385 488 23.2 1.03 0.31 - - - - - - - - 
CFS IBC Cardiochip  - 79 48 8 23.7 0.04 0.84 
100.0 - 45 58 32 45.2 2.38 0.12 
CHS IBC Cardiochip  - 2,344 1,381 225 23.2 1.31 0.25 
100.0 - 1,413 1,911 628 40.1 0.18 0.67 
EAS ABI TaqMan  - 518 287 46 22.3 0.57 0.45 
93.9 - 323 402 131 38.8 0.10 0.75 
ELSA KASPar  - 3,352 1,852 277 22.0 1.04 0.31 
- - - - - - - - 
Ely Metabochip  rs3761742 (1.00) 989 544 68 21.2 0.39 0.53 
- - - - - - - - 
EPIC-NL IBC Cardiochip  - 3,009 1,837 251 22.6 1.02 0.31 
- - - - - - - - 
ET2DS1 KASPar  - 690 311 52 19.71 4.68 0.03 
97.8 - 501 390 155 33.5 27.7 0.14 
MRC Fenland Metabochip  rs3761742 (1.00) 1,953 1,061 172 22.1 3.11 0.08 
- - - - - - - - 
FHS IBC Cardiochip  - 807 456 69 22.3 0.19 0.66 
100.0 - 491 647 198 39.0 0.41 0.52 
HAPIEE-CZ KASPar  - 3,996 2,384 341 22.8 0.26 0.55 
- - - - - - - - 
HAPIEE-LT KASPar  - 4,049 2,424 407 23.5 3.04 0.08 
- - - - - - - - 
HAPIEE-PL KASPar  - 3,456 1,988 282 22.3 0.03 0.86 
- - - - - - - - 
HAPIEE-RU KASPar  - 4,264 2,423 377 22.5 1.82 0.18 
- - - - - - - - 
IMPROVE Metabochip  - 1,937 1,310 215 25.1 0.11 0.74 
100.0 - 1,081 1,748 636 43.6 2.32 0.13 
InterAct Illumina 660W/ Sequenom/ ABI TaqMan 100.0 rs3761742 (1.00) 11,843 6,209 838 20.9 0.45 0.50 
100.0 - 3,122 9,138 6,634 40.7 0.07 0.79 
JUPITER Illumina Omni 1M Quad 100.0 - 5,363 2,983 403 21.7 0.21 0.65 100.0 - 3,249 4,157 1,340 39.1 0.03 0.86 
MESA IBC Cardiochip 100.0 - 1,333 829 135 23.9 0.17 0.68 100.0 - 792 1,138 368 40.77 1.47 0.22 
MRC NSHD KASPar 95.8 - 1,432 830 140 23.1 1.82 0.18 100.0 - 1,048 967 387 36.2 39.9 2.7x10-10 
NPHS-II ABI TaqMan  - 1,646 923 131 21.9 0.01 0.91 
100.0 - 960 1,286 456 41.1 0.10 0.75 
PROSPER Illumina 660K >97.5 rs3761742 (1.00) 3,307 1,710 227 20.6 0.10 0.75 - - - - - - - - 
SMART KASPar 99.4 - 4,915 3,007 449 23.3 0.15 0.70 - - - - - - - - 
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Abbreviations: HWE - Hardy-Weinberg equilibrium; MAF - minor allele frequency; LD – linkage disequilibrium 
*Linkage disequilibrium data derived from 1000 Genomes Pilot 1 
1 Minor allele frequency in diabetes cases 
 
TPT ABI TaqMan  - 2,349 1,403 197 22.8 0.45 0.50 
- - - - - - - - 
UCP IBC Cardiochip  - 973 556 102 23.3 3.48 0.06 
- - - - - - - - 
WGHS Illumin HumanHap Duo+ 100.0 rs1051795 (0.95) 14,559 7,708 1,020 20.9 2.84x10-5 0.99 99.99 - 8,260 11,213 3,818 40.5 0.02 0.90 
WHI IBC Cardiochip  - 3,442 1,779 316 21.8 17.85 2x10
-5 100.0 - 2,042 2,692 981 40.7 3.37 0.07 
Whitehall II IBC Cardiochip  - 3,020 1,765 252 22.5 0.08 0.78 
99.8 - 1,794 2,421 832 40.5 0.10 0.75 
 26 
Supplementary Table 3 - Collaborating genetic study characteristics   
 
Study name Study design Geographical location Sampling frame Participants included Baseline year(s) % Male Age (Mean ,SD) Fasting blood samples? 
      
 
 
 
AAA RCT  UK General practice 2,250 1998-2001 28.5 61.9 (6.6) No 
ARIC  Cohort  USA  Community 9,586 1986 53.5 54.3 (5.7)  
BRHS  Cohort UK General practice 3,876 1978-1980 100 68.7 (5.5)  
BWHHS  Cohort UK General practice 3,440 1999-2001 0 69.3 (5.5)  
CaPS Cohort UK Community 1,405 1984-1988 100 56.7 (4.4)  
CARDIA  Cohort  USA  Community 1,443 1985-1986 53.4 25.6 (3.4)  
CCHS Cohort Denmark Population 9,405 1990-2003 44.2 56 .7 (16) No 
CFS  Cohort  USA  Community (family) 135 1995 41.5 53.9 (14.7)  
CHS  Cohort  USA  Community 3,950 1989 45.0 70.4 (5.3) Yes 
deCODE Cohort Iceland Population, clinic 24,650 - - - - 
DGDG C-C France Clinic, population 1,376 - - - - 
DGI  C-C Finland, Sweden Population 2,097 - 47.7 - - 
EAS  Cohort UK General practices 851 1987 50.8 64.3 (5.6) Yes 
ELSA  Cohort UK HSE respondents 5,481 1998, 1999, 2001 45.6 61.0 (9.6)  
Ely  Cohort UK General practice 1,601 1990-1992 47.0 61.1 (9.2)  
EPIC-NL   Nested C-Ct Netherlands Population 5,194 1993-1997 21.9 54.1 (10.1) No 
ET2DS  Cohort UK Community (cases) 1,053 2006-2007 50.3 67.9 (4.2) Yes 
EUROSPAN C-C Europe Population 3,978 - - - - 
MRC Fenland Cohort UK General practices 3,186 2004 (ongoing) 46.0 46.9 (7.1)  
FHS  Cohort  USA  Community 1,332 1948/1971/2002 52.7 45.7 (10.1)  
FUSION C-C Finland Community 2,335 - - - - 
HAPIEE-Czech Republic Cohort Czech Republic Population 6,721 2002-2005 46.6 58.3 (7.1)  
HAPIEE-Lithuania Cohort Lithuania Population 6,880 2006-2008 45.4 61.0 (7.6)  
HAPIEE-Poland Cohort Poland Population 5,726 2002-2005 45.4 57.6 (6.9)  
HAPIEE-Russia Cohort Russia Population 7,064 2002-2005 45.6 58.9 (7.1)  
IMPROVE  Cohort Europe Clinic 3,462 2004 48.3 64.2 (5.4) Yes 
InterAct Cohort Europe Population 18,894 1991 49.7 55.6  
JUPITER RCT America, Europe, Africa Clinic 8,749 2003-2005 67.8 66.1 Yes 
KORAgen Nested C-C Germany Population 1,871 - - - - 
MESA  Cohort  USA  Population 2,297 2000-2002 47.8 62.7 (10.2) Yes 
MRC NSHD Birth cohort UK Birth register 2,402 1946 49.8 53.0 (0.0) No 
NPHS-II  Cohort UK General practices 2,700 1989-1994 100 56.6 (3.4)  
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PREVEND Prospective Netherlands Population 3,649 1997 51   
PROSPER RCT  Europe Clinic 5,804 1997-1999 48.3 75.3 (3.3) Yes 
Rotterdam Nested C-C Netherlands Population 5,939 - - - - 
SMART Cohort Netherlands Clinic 8,371 1996-2011 65.1 56.5 (12.4) Yes 
TPT RCT UK General practice 3,949 1984-1989 100 57.4 (6.7)  
UCP Nested C-C Netherlands Clinic 1,631 2007 74.5 62.8 (9.6)  
WGHS RCT North America Professional 23,294 1992-1994 0 54.7 Yes 
WHI Nested C-C  USA  Community 5,537 1994-1998 0 68.1 (6.6) Yes 
Whitehall II  Cohort UK Workplace 5,037 1985-1988 73.6 49.2 (6.0)  
WTCCC C-C UK Population 4,862 - - - - 
 
Abbreviations: C-C : case-control; C-Ct: case-cohort; HSE - Health Survey for England 
- : Data unavailable
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Supplementary Table 4 - Data availability for biomarkers and events in studies contributing to the primary genetic analysis 
 
 
Biomarkers Clinical events 
(prevalent & incident) 
 
Total chol. LDL-C Non-HDL-C Weight BMI Waist circ. Hip circ. Waist:hip ratio Plasma glucose Plasma insulin Diabetes mellitus 
AAA 2,242 - - - - - - - - - 48 
ARIC 9,567 9,412 9,567 9,578 9,578 9,576 9,576 9,575 7,740 9,578 1,184 
BRHS 3,855 3,746 3,740 3,867 3,873 3,850 3,859 3,848 3,856 - 294 
BWHHS 3,257 3,177 3,253 3,249 3,243 3,233 3,236 3,239 3,252 3,274 439 
CaPS 1,338 1,299 - 1,376 1,360 1,354 1,353 1,352 1,339 696 117 
CARDIA 1,436 1,436 1,436 1,438 1,437 1,436 1,437 1,436 1,331 1,321 99 
CCHS 9,394 9,379 9,388 9,385 9,382 9,364 9,365 9,365 - - 843 
CFS 39 38 39 134 134 45 45 45 39 39 17 
CHS 3,941 - 3,936 - 3,938 - - - 3,936 - - 
deCODE - - - - - - - - - - 1,456 
DGDG - - - - - - - - - - 679 
DGI - - - - - - - - - - 1,022 
EAS 850 846 846 851 851 - - - 849 - 30 
ELSA 5,449 5,304 5,447 5,323 5,235 5,362 5,351 5,346 - - - 
Ely 1,600 1,597 - 1,599 1,598 1,588 1,587 1,586 1,598 1,596 89 
EPIC-NL  4,337 4,261 3,060 5,186 5,185 5,181 5,181 5,179 3,455 - 1,110 
ET2DS 1,025 - 1,025 1,032 1,032 1,028 1,028 1,028 1,021 - 1,053 
EUROSPAN - - - - - - - - - - 268 
MRC Fenland 3,180 3,155 - 3,184 3,184 3,183 3,183 3,182 3,178 3,148 38 
FHS 845 844 844 858 316 785 784 783 825 749 161 
FUSION - - - - - - - - - - 1,161 
HAPIEE-CZ 6,568 6,301 6,543 6,719 6,716 - - 6,708 914 - 355 
HAPIEE-LT 6,838 6,655 6,720 6,874 6,874 - - 6,873 6,708 - 389 
HAPIEE-PL 5,720 5,647 5,720 5,720 5,716 - - 5,719 5,713 - 423 
HAPIEE-RU 7,062 7,058 7,060 7,064 7,063 - - 7,061 1,042 - 254 
IMPROVE 3,456 3,395 - 3,461 3,461 3,462 3,462 3,462 3,455 - 858 
InterAct - - - - - - - - - - 8,247 
JUPITER - - - 8,729 8,723 - - - - - 279 
KORAgen - - - - - - - - - - 433 
MESA 2,292 2,260 2,290 2,297 2,297 2,297 2,297 2,297 2,292 - 220 
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Abbreviations: TC - total cholesterol; HDL-C - high density lipoprotein cholesterol; LDL-C - low density lipoprotein cholesterol 
 
MRC NSHD 2,236 2,072 2,082 2,382 2,379 2,961 2,388 2,957 - - - 
NPHS-II 2,680 1,703 1,789 2,698 2,697 - - - - - 221 
PREVEND 3,626 3,496 3,554 3,623 3,622 3,622 3,622 3,622 3,465 3,402 140 
PROSPER 5,244 5,242 - 5,243 5,242 - - - 5,060 5,032 269 
Rotterdam - - - - - - - - - - 1,178 
SMART 7,897 7,448 7,879 7,925 7,924 6,715 6,713 6,716 7,879 4,373 - 
TPT 3,912 - - 3,932 3,932 - - - - - - 
UCP - - - 1,592 1,487 - - - - - - 
WGHS - - - 23,043 23,291 - - - - - 1,444 
WHI 2,920 1,472 2,861 - 5,489 - - - - - 272 
Whitehall II 4,739 4,658 4,724 4,752 4,746 4,693 4,692 4,688 4,543 4,245 334 
WTCCC - - - - - - - - - - 1,924 
Total 117,545 101,901 84,415 143,114 152,005 69,735 69,159 96,067 73,490 37,453 27,348 
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Supplementary Table 5 - Clinical outcome definitions  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: n/a - T2D data not included in analysis; - - T2D definition information unavailable 
 Diabetes (all aetiology, prevalent 
& incident) 
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AAA ● ●  
ARIC  ● ● 
BRHS  ●  
BWHHS ● ●  
CaPS ● ● ● 
CARDIA ● ● ● 
CCHS  ●  
CFS  ●  
CHS  ● ● 
deCODE - - - 
EAS ●   
ELSA n/a n/a n/a 
Ely n/a n/a n/a 
EPIC-NL ● ●  
ET2DS  ● ● 
EUROSPAN - - - 
MRC Fenland n/a n/a n/a 
FHS  ●  
FUSION - - - 
HAPIEE-CZ ●   
HAPIEE-LT ●   
HAPIEE-PL ●   
HAPIEE-RU ●   
IMPROVE n/a n/a n/a 
InterAct ● ● ● 
JUPITER  ● ● 
KORAgen    
MESA ●  ● 
MRC NSHD n/a n/a n/a 
NPHS-II ● ●  
PROSPER  ● ● 
Rotterdam - - - 
SMART n/a n/a n/a 
TPT  ●  
WGHS ● ● - 
WHI ●   
Whitehall II ● ● ● 
WTCCC - - - 
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Supplementary Table 6 – Associations of HMGCR rs17238484 with biomarkers and T2D risk in pre-
specified subgroups.  
P-values are for meta-regression between subgroup strata. 
 
 Tertiles of non-HDL-C 
Biomarker Low Mid High  
 Estimate (95% CI) Meta-regression p-value 
LDL-C (mmol/L) -0.013 (-0.022 to -0.004) -0.013 (-0.021 to -0.006) -0.034 (-0.047 to -0.020) 0.055 
Plasma glucose (%) 1.658 (-0.386 to 3.744) 2.364 (0.281 to 4.490) 1.923 (-0.201 to 4.092) 0.855 
Plasma insulin (%) 4.628 (1.451 to 7.905) 3.761 (0.625 to 6.995) 2.884 (-0.089 to 5.946) 0.445 
BMI (kg/m2) 0.035 (0.018 to 0.052) 0.035 (0.018 to 0.052) 0.029 (0.012 to 0.045) 0.596 
Body weight (kg) 0.032 (0.013 to 0.050) 0.042 (0.024 to 0.060) 0.020 (0.002 to 0.037) 0.354 
  
  
 Lipid-lowering drug use 
Biomarker Users Non-users   
 Estimate (95% CI)  Meta-regression p-value 
LDL-C (mmol/L) -0.044 (-0.072 to -0.016) -0.075 (-0.088 to -0.062)  0.122 
Plasma glucose (%) 1.531 (-1.460 to 4.613) 0.773 (-0.909 to 2.483)  0.671 
Plasma insulin (%) 5.265 (0.562 to 10.189) 2.987 (0.424 to 5.615)  0.423 
BMI (kg/m2) 0.039 (0.013 to 0.065) 0.025 (0.013 to 0.038)  0.349 
Body weight (kg) 0.035 (0.008 to 0.062) 0.023 (0.010 to 0.036)  0.448 
T2D (odds ratio) 0.981 (0.890 to 1.082) 1.038 (0.985 to 1.094)  0.316 
  
 BMI classes 
Biomarker Normal (<25) Overweight (25-30) Obese (>30)  
 Estimate (95% CI) Meta-regression p-value 
LDL-C (mmol/L) -0.073 (-0.090 to -0.056) -0.059 (-0.076 to -0.043) -0.070 (-0.092 to -0.048) 0.247 
Plasma glucose (%) 1.631 (0.033 to 3.254) 0.199 (-1.565 to 1.994) 1.126 (-1.935 to 4.282) 0.249 
Plasma insulin (%) 2.558 (0.136 to 5.039) -0.130 (-2.622 to 2.426) 2.488 (-1.422 to 6.552) 0.150 
BMI (kg/m2) - - - - 
Body weight (kg) 0.007 (-0.003 to 0.017) 0.011 (0.002 to 0.021) 0.007 (-0.012 to 0.026) 0.538 
  
 Sex 
Biomarker  Male Female   
 Estimate (95% CI)  Meta-regression p-value 
LDL-C (mmol/L) -0.065 (-0.079 to -0.051) -0.061 (-0.076 to -0.046)  0.909 
Plasma glucose (%) 0.881 (-0.823 to 2.613) 2.097 (0.326 to 3.900)  0.346 
Plasma insulin (%) 2.054 (-0.495 to 4.668) 2.868 (0.350 to 5.450)  0.665 
BMI (kg/m2) 0.019 (0.007 to 0.031) 0.032 (0.017 to 0.046)  0.197 
Body weight (kg) 0.022 (0.009 to 0.034) 0.026 (0.012 to 0.039)  0.650 
  
 T2D cases/controls 
Biomarker Cases Controls   
 Estimate (95% CI)  Meta-regression p-value 
LDL-C (mmol/L) -0.051 (-0.085 to -0.016) -0.065 (-0.077 to -0.053)  0.570 
Plasma glucose (%) -2.704 (-7.494 to 2.335) 0.698 (-0.306 to 1.712)  0.199 
Plasma insulin (%) 0.245 (-6.159 to 7.086) 1.945 (0.012 to 3.915)  0.637 
BMI (kg/m2) 0.022 (-0.011 to 0.055) 0.024 (0.013 to 0.035)  0.906 
Body weight (kg) -0.003 (-0.035 to 0.030) 0.024 (0.012 to 0.035)  0.136 
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Supplementary Table 7 – Associations of HMGCR rs12916 with plasma lipids, T2D-related biomarkers and T2D risk – fixed effects meta-analysis 
 
 rs12916 Heterogeneity 
Biomarker Total n (studies) Per-allele effect 95% CI Effect p-
value 
I2 Heterogeneity 
p-value 
       
Total cholesterol (mmol/L) 40,712 (15)  -0.077 -0.091 to -0.062 4.74x10-25 27.5 0.15 
LDL-C (mmol/L) 32,674 (13) -0.083 -0.098 to -0.068 4.40x10-28 33.3 0.12 
Non-HDL-C (mmol/L) 39,591 (15) -0.074 -0.089 to -0.059 9.50x10-22 28.2 0.15 
Plasma insulin (%) 19,918 (7) 0.659 -0.631 to 1.967 0.318 44.4 010 
Plasma glucose (%) 30,641 (12) 0.125 -0.135 to 0.387 0.35 0.0 0.54 
Body weight (kg) 65,871 (15) 0.203 0.043 to 0.362 0.01 0.0 0.84 
BMI (kg/m2) 75,140 (17) 0.083 0.031 to 0.135 1.62x10-3 0.0 0.90 
Height (m) 39,771, (14) 0.0001 -0.001 to 0.001 0.77 0 0.67 
Waist circumference (cm) 30,313 (11) 0.303 0.102 to 0.504 0.003 0 0.55 
Hip circumference (cm) 30,313 (11) 0.193 0.050 to 0.337 8.07x10-3 28.6 0.17 
       
Outcome No. of cases/controls 
(studies) 
Per-allele odds 
ratio 
95% CI Effect p-
value 
I2 Heterogeneity 
p-value 
T2D 14,976/73,574 (16) 1.06 1.03 to 1.09 9.58x10-5 36.7 0.07 
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Supplementary Table 8 - Associations of rs17238484 and rs12916 with T2D-related biomarkers and T2D risk - random effects meta-analyses 
rs17238484 Biomarker  No. of individuals (studies) Per-allele beta coefficient 95% confidence interval Effect p-
value 
 LDL-C (mmol/L) 101,919 (26) -0.065 -0.077 to -0.052 6.20x10-25 
 Total cholesterol (mmol/L) 117,545 (30) -0.067 -0.079 to -0.055 4.60x10-30 
 Non-HDL-C (mmol/L) 103,375 (27) -0.067 -0.081 to -0.053 1.20x10-21 
 Body weight (kg) 143,113 (30) 0.301 0.175 to 0.428 3.20x10-6 
 BMI (kg/m2) 152,004 (32) 0.105 0.066 to 0.145 1.80x10-7 
 Height (m) 77,291 (23) 0.001 -0.000 to 0.002 0.23 
 Waist circumference (cm) 69,163 (19) 0.315 0.158 to 0.472 8.30x10-5 
 Hip circumference (cm) 69,159 (19) 0.211 0.101 to 0.321 1.70x10-4 
 Plasma glucose (%) 73,490 (23) 0.230 0.020 to 0.441 0.03 
 Plasma insulin (%) 37,453 (12) 0.016 0.005 to 0.027 3.60x10-3 
      
 Outcome No. of cases/controls (studies) Odds ratio 95% confidence interval p-value 
 T2DM 26,236/164,021 (35) 1.02 1.00 to 1.04 0.10 
      
rs12916 Biomarker  No. of individuals (studies) Per-allele beta coefficient 95% confidence interval Effect p-
value 
 LDL-C (mmol/L) 32,674 (13) -0.081 -0.101 to -0.062 5.50x10-16 
 Total cholesterol (mmol/L) 40,712 (15) -0.075 -0.093 to -0.057 7.20x10-16 
 Non-HDL-C (mmol/L) 39,591 (15) -0.072 -0.091 to -0.053 8.10x10-14 
 Body weight (kg) 65,871 (15) 0.203 0.043 to 0.362 0.01 
 BMI (kg/m2) 75,140 (17) 0.083 0.031 to 0.135 1.60x10-3 
 Waist circumference (cm) 39,771 (14) 0.000 -0.001 to 0.001 0.77 
 Hip circumference (cm) 30,313 (11) 0.303 0.102 to 0.504 3.10x10-3 
 Plasma glucose (%) 30,313 (11) 0.195 0.008 to 0.382 0.04 
 Plasma insulin (%) 30,641 (12) 0.130 -0.140 to 0.391 0.35 
 Height (m) 19,918 (7) 0.004 -0.016 to 0.023 0.72 
      
 Outcome No. of cases/controls (studies) Odds ratio 95% confidence interval p-value 
 T2DM 14,976/73,574 (16) 1.07 1.02 to 1.12 1.10x10-3 
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Supplementary Table 9 – Effect of statin therapy on body weight and new-onset T2D risk– fixed 
effects meta-analysis 
 
 
Trials Weight change (kg) 95 % CI 
   
Placebo- or standard care- controlled 0.33  0.26 to 0.41 
Intensive vs moderate dose -0.08 -0.16 to 0.01 
   
All trials combined 0.16 0.11 to 0.22 
   
 
 
Trials T2D Odds Ratio 95 % CI 
   
Placebo- or standard care- controlled 1.12 1.05 to 1.19 
Intensive vs moderate dose 1.12 1.04 to 1.22 
   
All trials combined 1.12 1.07 to 1.17 
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Supplementary Table 10 – Associations of HMGCR rs17238484 and rs12916 with T2D risk in 35 
studies contributing to this analysis, and in combination with data from GWA study data from the 
DIAGRAM consortium 
 
 rs17238484-G  rs12916-T 
 OR (95% CI) Cases/controls or total 
n (studies) 
 OR (95% CI) Cases/controls or total 
n (studies) 
      
Risk of T2D: original 
studies 
1.02 (1.00 to 1.05) 26,236/164,021 (35)  1.06 (1.03 to 1.09) 14,976/73,574 (16) 
      
Risk of T2D: Morris 
GWAS+Metabochip 
analysis 
1.03 (0.99 to 1.06) 51,943 (19)*  1.01 (0.99 to 1.04) 76,774 (19)* 
      
Risk of T2D: original 
studies + unique Morris 
data 
1.03 (1.01 to 1.06) 181,111 (38)*  1.02 (1.00 to 1.04) 151,329 (38)* 
 
 
Estimates shown are derived from i) 35 observational population studies contributing to the 
current analysis; ii) Morris et al. GWAS+Metabochip studies consortium; iii) meta-analysis of 
original studies and studies contributing to the current analysis combined with the remaining 
studies unique to the Morris et al. consortium. 
 
Effective sample size as reported by the DIAGRAM consortium at  
http://diagram-consortium.org/downloads.htm 
*Numbers of cases and controls unavailable from Morris et al. data
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Supplementary Figure 1 - Associations of SNPs at the HMGCR locus with LDL-C concentration and 
liver gene expression  
 
The x-axis shows the physical position on chromosome 5 (Mb). Each dot represents one variant (SNP 
or indel - imputed or directly typed). Upper panel graph y-axis uses p-values from a published meta-
analysis of LDL-C levels in >100,000 individuals50. Lower panel y-axis shows the -log10p-value for 
association with HMGCR gene expression in liver. The posterior probability ("Post P") that LDL-C co-
localises with HMGCR liver expression is shown on top of the graph. There is a high probability that 
HMGCR expression is mediating the LDL-C signal. 
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Supplementary Figure 2 - Effect of HMGCR rs12916 genotype on liver expression of HMGCR 
946 individuals had expression measurements and genotypes that were directly typed or imputed 
(uncertain genotypes were removed). The allele T of the SNP rs12916 is associated with a decreased 
effect of HMGCR expression in liver (1-d.f. p=1.3x10-5). 
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Supplementary Figure 3 - Genetic analysis biomarker data - box and whisker plots 
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Supplementary Figure 4 – Meta-regression model of the relationship between new-onset diabetes 
and percentage LDL-C reduction in statin trials at 1 year  
20 trials, meta-regression p=0.10. Shaded area represents 95% confidence interval. The size of 
markers is determined by the standard error of the within-trial estimate of T2D odds ratio. 
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Supplementary Figure 5 –Meta-regression model of the relationship between change in weight and 
relative change in LDL-C in statin trials at 1 year  
15 trials, meta-regression p=0.58. Shaded area represents 95% confidence interval. The size of 
markers is determined by the standard error of within-trial estimates of weight change. 
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